Status:
UNKNOWN
FACILITY: Feeding the fAmiLy: the Intergenerational approaCh to fIght obesiTY
Lead Sponsor:
Buzzi Children's Hospital
Collaborating Sponsors:
University of Pavia
Conditions:
Obesity
Obesity, Childhood
Eligibility:
All Genders
2+ years
Brief Summary
The FACILITY STUDY is aimed at evaluating maternal and children social, cultural, economic and lifestyle-related risk factors for the development of childhood overweight, obesity and early adiposity r...
Detailed Description
The FACILITY retrospective case-control study is conducted in one Italian hospital in Milan (Buzzi Children's Hospital) on children and adolescents (2-18 years old) with EAR and their mothers (≥ 18 ye...
Eligibility Criteria
Inclusion
- Inclusion criteria (CASE GROUP)
- For mothers:
- Age ≥ 18 years old;
- Admitted to the Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy;
- Written and signed informed consent.
- For the children/adolescent:
- Age \> 2 years and \< 18 years old;
- Early adiposity rebound (\< 5 years of age);
- Overweight (between 2-3 Z-score) and obesity (≥ 3 Z-score) diagnosis according to the CDC growth charts.
- Admitted to the Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy;
- Mother and father/legal guardian had written and signed informed consent.
- Inclusion criteria (CONTROL GROUP)
- For mothers:
- Age ≥ 18 years old;
- Admitted to the Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy;
- Written and signed informed consent.
- For the children/adolescent:
- Age \> 2 years and \< 18 years old;
- Early adiposity rebound (\< 5 years of age);
- Admitted to the Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy;
- Mother and father/legal guardian had written and signed informed consent.
- Exclusion criteria (CASE GROUP and CONTROL GROUP)
- For the mothers:
- Mother had not written and signed informed consent;
- Inability to understand the Italian and English language.
- For the children/adolescent:
- Endocrine disorders (hypothyroidism, hypercortisolism, growth hormone deficiency);
- Central nervous system damage (hypothalamic-pituitary damage because of surgery or trauma);
- Genetic diseases either monogenic (leptin deficiency, MC4R mutation) or pleiotropic genetic syndromes (Prader-Willi, Bardet-Biedl);
- Mother and father/legal guardian had not written and signed informed consent.
Exclusion
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
269 Patients enrolled
Trial Details
Trial ID
NCT06164340
Start Date
December 1 2023
End Date
December 1 2025
Last Update
December 18 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.